Cycle view
- Bloc
- Organisation
- Théorie
- Pratique
- Autres
- Crédits
| Code | Détails | Bloc | Organisation | Théorie | Pratique | Autres | Crédits |
|---|---|---|---|---|---|---|---|
| PHIN2004-1 | Active substances | B1 | TA | 6 | |||
| Substances issues de recherches pharmacochimiques, part a | 10 | - | - | ||||
| Substances issues de recherches pharmacochimiques, part b
Françoise Dufrasne
| 5 | - | - | ||||
| Substances issues des biotechnologies
David Vermijlen
| 15 | - | - | ||||
| Substances d'origine naturelle, part a
Joëlle Quetin-Leclercq
| 5 | - | - | ||||
| Substances d'origine naturelle, part b
Pierre Duez
| 5 | - | - | ||||
| Produits radiopharmaceutiques
Ghanem Ghanem
| 10 | - | - | ||||
| PHIN2008-2 | Clinical viewpoints | B1 | Q1 | 6 | |||
| Métabolisme des médicaments et paramètres pharmacocinétiques
François-Xavier Mathy
| 20 | - | - | ||||
| Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) | 15 | - | - | ||||
| Information et pharmacovigilance | 10 | - | - | ||||
| PHIN2013-2 | Quality assurance and pharmaceutical management | B1 | 7 | ||||
| Principles of pharmaceutical management | 10 | - | - | ||||
| Quality assurance, part a : basic concepts and quality assurance organisation
Thierry Pronce
| 20 | - | - | ||||
| Quality assurance, part b : Analytical technology of procedures and risk analysis
Xavier Marcelis
| 7,5 | - | - | ||||
| English applied to the pharmaceutical industry
Jacques Poupaert, Nevin Serbest
| 20 | - | - | ||||
| Pharmaceutical marketing
Vincent Bierlaire
| 7,5 | - | - | ||||
| PHIN2033-1 | Industrial pharmaceutical technology | B1 | 8 | ||||
| Industrial pharmaceutical microbiology
Véronique Fontaine
| 15 | - | - | ||||
| Preformulation and selection of galenical forms
Karim Amighi
| 15 | - | - | ||||
| Industrial production of galenical forms | 15 | - | - | ||||
| Industrial production of biomolecules
Rita Van Bever
| 15 | - | - | ||||
| Industrial aspects of technological development including packaging | 10 | - | - | ||||
| PHIN2023-1 | Drug analysis | B1 | 7 | ||||
| Analytical methods and pharmaceutical and biopharmaceutical control, part a
Jean-Michel Kauffman, Pierre Van Antwerpen
| 10 | - | - | ||||
| Analytical methods and pharmaceutical and biopharmaceutical control, part b | 10 | - | - | ||||
| Methods in pharmaceutical and biopharmaceutical analysis, part a : Validation and qualification of equipment | 15 | - | - | ||||
| Methods in pharmaceutical and biopharmaceutical analysis, part b : Process analytical technology | 5 | - | - | ||||
| Statistical methods applied to the pharmaceutical industry
Laure Elens
| 15 | - | - | ||||
| Experimental planning and "quality by design" | 10 | - | - | ||||
| PHIN2029-2 | Regulation and the medical-social environment | B1 | 8 | ||||
| Economic aspects of drug development
Dominique Martin
| 10 | - | - | ||||
| Legislation and procedures applied to pharmaceutical industry, part a : legislation
Catherine Druez
| 10 | 5 | - | ||||
| Legislation and procedures applied to pharmaceutical industry, part b : patents and protection
Patrick Di Stefano
| 5 | - | - | ||||
| Macroeconomic environment and pharmaco-economics
Pierre Duez
| 10 | - | - | ||||
| CTD File (Common Technical Document)
Jean-Antoine De Muylder
| 15 | - | - | ||||
| Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files
Sonia Beken
| 15 | - | - | ||||
| Regulations of preclinical and clinical studies, part b : clinical studies
Anne Lenaers
| 5 | - | - | ||||
| Regulations of preclinical and clinical studies, part c : pediatric studies
Daniel Brasseur
| 2,5 | - | - | ||||
| Specific regulatory issues, part a : medicine and herbal dietary supplement | 5 | - | - | ||||
| Specific regulatory issues, part b : Preformulation and galenical development documentation
Francis Vanderbist
| 5 | - | - | ||||
| PHIN2032-1 | Visits and seminars organised in the pharmaceutical industry - [77,5h Visit]
Françoise Dufrasne, Marianne Fillet, Rita Van Bever
| B1 | - | - | [+] | 3 | |
| MTFE2000-1 | Final work | B1 | - | - | - | 15 |